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A divergent approach to benzylisoquinoline-type
and oxoaporphine alkaloids via regioselective
direct ring metalation of alkoxy isoquinolines†
Benedikt Melzer and Franz Bracher*
Methoxy- and benzyloxy-substituted isoquinolines are regioselectively metalated at C-1 with the
Knochel–Hauser base, subsequent trapping with aromatic aldehydes gives aryl(isoquinolin-1-yl)carbinols
as building blocks for divergent syntheses of different types of benzylisoquinoline alkaloids. Photochemi-
cal cyclization of ortho-bromo analogues under reductive conditions gives oxoaporphine alkaloids. Nine
benzylisoquinoline alkaloids and two oxoaporphine alkaloids were obtained in two or three steps from
appropriate isoquinolines.
Introduction
Benzylisoquinoline alkaloids are a large group of plant second-
ary metabolites which includes about 2500 known structures.
Besides simple benzylisoquinolines, more complex tetracyclic
ring systems (aporphines, protoberberines, cularines, pavines)
and the pentacyclic morphinane-type alkaloids belong to this
class. All these alkaloids share a common biosynthetic origin,
with (S)-norcoclaurine, a metabolite formed by condensation
of dopamine and 4-hydroxyphenylacetaldehyde, as the first
common intermediate. Manifold biological activities have
been reported for alkaloids from this class, among them nar-
cotic, spasmolytic, dopaminergic, ion-channel modulating,
and cytotoxic properties. A timely review of structures, biosyn-
thesis and pharmacology of benzylisoquinoline alkaloids is
provided by Hagel and Facchini.1
Benzylisoquinoline alkaloids in the narrower sense bear up
to three oxygen functions (hydroxy, methoxy, methylenedioxy)
on the carbocyclic part of the isoquinoline, and one or more
oxygen functions at the benzylic ring; the benzylic carbon is a
methylene group in most cases, but can also be a carbinol (or
its methyl ether) or a carbonyl group (Fig. 1).
Classical synthetic approaches to the benzylisoquinoline
alkaloids are inspired by the biosynthesis and include acid-
mediated cyclizations of arylacetamides (Bischler-Napieralski)
or arylacetaldimines of phenylethylamines (Pictet-Spengler),
followed by a dehydrogenation step.2 Alternatively, isoquino-
lines can be benzylated at C-1 via N-benzoyl-1,2-dihydroisoqui-
noline-1-carbonitriles (Reissert synthesis3), but this method
suffers from the need to use stoichiometric amounts of toxic
cyanide. For the preparation of alkaloids containing a C-1 sub-
stituent other than methylene, laborious variants of these
methodologies must be applied.4–9 A Pomeranz-Fritsch
approach to benzylisoquinolines through cyclization of
complex 2-aryl arylethylaminoacetaldehyde acetals was found
to have a very narrow scope.10,11 A convenient access to 1-ben-
zoylisoquinolines has been developed recently, utilizing direct
acylation of isoquinolines at C-1 with benzoyl radicals.12,13
Other approaches start from 1-iodoisoquinolines, and consist
of either nucleophilic substitution with deprotonated arylace-
tonitriles, followed by oxidation,14 or zinc insertion followed
by copper-catalyzed coupling with an aroyl chloride.15
Fig. 1 New approach to benzylisoquinoline and oxoaporphine alkaloids
via regioselective metalation of substituted isoquinolines.
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In continuation of our recent work on the synthesis of aro-
matic alkaloids using direct ring metalations of heterocycles
as the crucial step,16,17 we intended to work out a novel, flexi-
ble approach to benzylisoquinoline alkaloids. This work was
inspired by two single reports of Knochel on the direct metala-
tion of isoquinoline18 and 6,7-dimethoxyisoquinoline19 at C-1
with the hindered amide base TMPMgCl·LiCl. Quenching with
iodine, followed by Pd-catalyzed Negishi cross-coupling of the
1-iodoisoquinoline with a benzylzinc reagent gave the benzyl-
isoquinoline alkaloid papaverine (9), whereas attempted direct
cross-coupling of the magnesiated isoquinoline with a benzyl
chloride did not provide the alkaloid.19 We envisaged to trap
1-magnesiated isoquinoline building blocks with appropriately
substituted benzaldehydes to obtain aryl(isoquinolin-1-yl)-
methanols, which in turn would open an access to benzyliso-
quinolines, benzoylisoquinolines, and 1′-methoxy-substituted
benzylisoquinolines in one single step (hydrogenolysis of the
benzylic hydroxy group, oxidation, or etherification) each. This
should represent a divergent approach to four common sub-
types of benzylisoquinoline alkaloids. Further, carbinols pre-
pared from ortho-bromo-substituted benzaldehydes should
open an access to oxoaporphine alkaloids via intramolecular
biaryl synthesis, utilizing either photochemical,14,20–22
radical23 or Pd-catalyzed24,25 reactions. The oxoaporphines are
of high pharmaceutical relevance due to their antibacterial,
antifungal, anticancer and other biological activities26,27
(Fig. 1).
Results and discussion
We started our investigations with 6,7-dimethoxyisoquinoline
(1a), since the metalation at C-1 with the Knochel–Hauser base
(TMPMgCl·LiCl) had been reported previously by the Knochel
group.19 Metalation with 1.5 equivalents of the base over 4 h at
room temperature, followed by reaction with various benz-
aldehydes 2 (1.5 equiv.) at 0 °C gave the expected racemic sec-
ondary alcohols 3a–d in moderate yields (37–53%) (Scheme 1).
One of these alcohols (3b) is the racemate of the alkaloid papa-
verinol (isolated from Papaver somniferum and other plants;
previously synthesized by either oxidation of papaverine (9)28
or reduction of papaveraldine (4)29), alcohol 3a is the dimethyl
ether of the alkaloid annocherin A (7).30 Side-reactions were
not observed, and significant amounts (up to 49%) of the start-
ing material 1a were recovered. Modifications of the reaction
conditions were examined in order to improve the yields. The
use of just 1.1 equivalents of TMPMgCl·LiCl led to lower yields
of the secondary alcohols. However, the use of 2.0 equivalents
TMPMgCl·LiCl did not increase the yields. Also longer reaction
times for the metalation step up to 16 h did not result in
higher yields. Attempted metalation with the “frustrated Lewis
pair” TMPMgCl·BF3·LiCl, a system which was applied to the
regioselective metalation of pyridines and quinolines before,31
failed completely due to spontaneous formation of a
precipitate.
In order to explore the scope of this methodology,
especially with view on alkaloids with other substitution pat-
terns in the isoquinoline part, we expanded our method to the
metalation of readily available isoquinolines 1b–d 32–34
(Scheme 1). The metalation of 5,6,7-trimethoxyisoquinoline
(1b) with TMPMgCl·LiCl (1.5 equiv.) at room temperature for
4 h, followed by reaction with 4-methoxybenzaldehyde (2a)
afforded the secondary alcohol 3e in 28% yield. The direct
metalation of 7-benzyloxy-6-methoxyisoquinoline (1c) under
the same reaction conditions and reaction with 4-(benzyloxy)-
benzaldeyhde (2e) provided the secondary alcohol 3f in 49%
yield. Unfortunately, any attempts to perform a controlled ring
metalation of 6,7-methylenedioxyisoquinoline (1d) failed. An
Scheme 1 Synthesis of secondary alcohols 3 from alkoxy-substituted isoquinolines 1.
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iodine quenching after a metalation experiment gave a poorly
separable mixture of iodinated products, from which <10% of
impure 8-iodo derivative was isolated. We further investigated
whether better yields can be obtained by activation of the aro-
matic aldehydes with a Lewis acid (BF3), but independent of
the sequence of addition of the components spontaneous pre-
cipitation was observed, and not even traces of the desired car-
binols were obtained.
Having the carbinols 3a–f in hand, divergent syntheses
were accomplished, leading to benzylisoquinoline alkaloids
bearing other functional groups at the benzylic C-1′ position.
Oxidation of the secondary alcohols 3b and 3e with manga-
nese(IV) oxide in refluxing dichloromethane for 6 h afforded
the natural products papaveraldine (4; isolated from Papaver
somniferum and other plants; first total synthesis by oxidation
of papaverine (9)35) in 68% and thalimicrinone (5; isolated
from Thalictrum minus var. microphyllum;36 first total synthesis
utilizing a Reissert-type reaction5) in 98% yield, respectively
(Scheme 2).
Deprotonation of the secondary alcohols 3b and 3c using
sodium hydride in dry DMF and subsequent reaction with
iodomethane over 2 h furnished the racemic O-methylated
alkaloids setigerine (6a; isolated from Papaver setigerum DC;37
first total synthesis from papaverinol (3b), see ref. 38) and seti-
geridine (6b; isolated from Papaver setigerum DC;37 first total
synthesis see ref. 9) in yields of 77% and 91%, respectively.
Analogous O-methylation of 3f under the same conditions led
to 6c, the central intermediate in the synthesis of annocherin
B (8), in 90% yield (Scheme 3).
By hydrogenolytic removal of both O-benzyl protective
groups in 3f and 6c in methanol over Pd/C catalyst (room
temperature for 24 h, 90 and 66% yields) the first total synth-
eses of the racemic alkaloids annocherin A (7) and annocherin
B (8; both isolated from Annona cherimola39) were completed.
The preparation of 7 was accomplished in just two steps
(overall yield 44%) starting from 7-benzyloxy-6-methoxyisoqui-
noline (1c), annocherin B (8) was synthesised in three steps
with an overall yield of 29% (Scheme 4).
Deoxygenation of the benzhydrol-type alcohol papaverinol
(3b) was found to be less feasible, and needed careful optimi-
zation of the reaction conditions. Finally, we found that hydro-
genation over Pd/C (10%) in a methanol/sulphuric acid
mixture at room temperature for 6 d gives the benzylisoquino-
line alkaloid papaverine (9; isolated from Papaver somniferum
and other plants; first total synthesis by Pictet and Gams40) in
60% yield. It was also possible to simultaneously remove the
O-benzyl protective group and deoxygenate the benzylic posi-
tion of compound 3d under these conditions to yield the alka-
loid palaudine (10; isolated from Papaver somniferum;41 first
total synthesis by O-demethylation of papaverine42) in 75%
yield (Scheme 4).
Having established a general access to variously substituted
benzylisoquinolines, we wished to extend this methodology to
the total synthesis of oxoaporphine alkaloids. As mentioned in
the introduction (Fig. 1), intermediates bearing ortho-bromo-
benzyl residues can be applied to intramolecular aryl–aryl
Scheme 2 Synthesis of the benzoylisoquinoline alkaloids papaveraldine
(4) and thalimicrinone (5).
Scheme 3 O-Methylation of the alcohols 3b,c,f to setigerine (6a), seti-
geridine (6b), and 6c.
Scheme 4 Synthesis of the alkaloids annocherin A (7), annocherin B
(8), papaverine (9), and palaudine (10) by multiple hydrogeneolyses.
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coupling reactions, and on the basis of literature data the
photochemical approach appeared most promising. Formally,
the pertinent 1-(2-bromobenzoyl)isoquinolines appear to be
the best substrates, but previous investigations revealed that
the corresponding carbinols are much more susceptible to this
cyclization, an oxidation of the carbinol to the keto group
obviously takes place after completed cyclization under the
workup conditions.20–22 Chuang et al.14 even reported a
“reductive photocyclization” of 1-(2-bromobenzoyl)isoquino-
lines to oxoaporphines, comprising an in situ reduction of the
starting ketones to the carbinols, followed by photocyclization
and aerial re-oxidation during workup. These insights made
our above-mentioned approach highly attractive, since it pro-
vides a direct access to the carbinols as the most promising
cyclization substrates.
Fortunately, the ring metalation/aldehyde quenching proto-
col could be applied to ortho-bromobenzaldehydes without
any problems. Reaction of C-1 magnesiated 6,7-dimethoxyiso-
quinoline with 2-bromobenzaldeyhde (11a) furnished carbinol
12a in 69% yield, with 6-bromovertraldehyde (11b) the carbinol
12b was obtained in 35% yield. A first attempt of a photocycli-
zation of 12a in methanol (concentration 2.5 mM) in a photo-
reactor (mercury vapour lamp, 125 W, 3 h) gave the expected
oxoaporphine alkaloid lysicamine (13; isolated from Lysichiton
camtschatcense Schott var. japonicum Makino;43 first total syn-
thesis starting from nuciferine44) in only 10% yield,
accompanied by numerous by-products. Longer reaction times
led to even more by-products. However, photocyclization in the
presence of NaBH4 (1.5 equivalents) proceeded well and pro-
vided lysicamine (13) in 53% yield after 3 h reaction time.
Obviously, it is suitable not only to use the carbinol as a start-
ing material, but also to suppress the formation of keto forms
of educt and product during the irradiation process, and then
rely on spontaneous oxidation during workup. Photo-induced
cyclization of alcohol 12b under the same conditions yielded
the oxoaporphine alkaloid oxoglaucine (14; isolated from Lirio-
dendron tulipifera, L.45 first total synthesis utilizing a Pschorr
cyclization starting from nitropapaveraldine46) in 59% in just
1 h (Scheme 5).
In conclusion, we worked out a new protocol for the syn-
thesis of aryl(isoquinolin-1-yl)carbinols by direct regioselective
metalation of alkoxy isoquinolines, followed by reaction with
aromatic aldehydes. These carbinols are versatile intermedi-
ates for divergent syntheses of benzylisoquinoline alkaloids
and oxoaporphines. Eleven alkaloids were synthesized using
this protocol in two (for 1′-methoxy compounds three) steps




All reactions were performed under nitrogen atmosphere with
flame-dried glassware, unless otherwise stated. Solvents used
were of HPLC grade or p.a. grade and/or purified according to
standard procedures. Photochemical reactions were conducted
using a HPK 125W high pressure mercury vapor lamp from
Heraeus Noblelight. Melting points were determined by open
tube capillary method with a Büchi melting point B-450 appar-
atus. IR measurements were carried out with a Perkin-Elmer
FTIR Paragon 1000 spectrometer. NMR spectra were recorded
with Jeol J NMR GX (400 or 500 MHz) and Avance III HD
Bruker BioSpin (400 or 500 MHz) spectrometers with residual
non-deuterated solvent as internal standard. Spectra were
recorded in deuterated solvents and chemical shifts are
reported in parts per million (ppm). J values are given in
Hertz. Multiplicities are abbreviated as follows: s = singlet, d =
doublet, t = triplet, m = multiplet. Signal assignments were
carried out based on 1H, 13C, HMBC, HMQC and COSY
spectra. NMR spectra were analyzed with the NMR software
MestReNova, Version 5.1.1-3092 (Mestrelab Research S.L.)
HRMS were performed by electron impact (EI) at 70 eV with a
Thermo Finnigan MAT 95 or a Jeol GCmate II spectrometer or
by electrospray ionization (ESI) with a Thermo Finnigan LTQ
FT Ultra Fourier Transform Ion Cyclotron resonance mass
spectrometer. Chromatographic purification of products was
performed by using flash column chromatography on Merck
silica gel 60 (0.015–0.040 mm) as stationary phase.
General procedure A (preparation of secondary alcohols
3a–f/12a–b)
A dry and nitrogen flushed 25 mL Schlenk tube, equipped with
a magnetic stirring bar, was charged with the appopriate iso-
quinoline 1a,b (1.00 mmol) in THF (4 mL) or 1c (2.00 mmol)
in dry THF (6 mL). TMPMgCl·LiCl (1.50 equiv., 1.0 M in THF/
toluene) was added to this solution dropwise over 2 min. The
reaction mixture was stirred at room temperature for 4 h. After
cooling to 0 °C the corresponding benzaldehyde 2a–e/11a–b
Scheme 5 Synthesis of the oxoaporphine alkaloids lysicamine (13) and
oxoglaucine (14).
Organic & Biomolecular Chemistry Paper























































































(1.50 equiv.), dissolved in dry THF (2 mL), was added dropwise
to the reation mixture. The mixture was allowed to warm to
room temperature within 16 h. Then the mixture was
quenched with satd. aqueous NH4Cl solution (4 mL) and
extracted with dichloromethane (3 × 20 mL). The combined
organic layers were dried with Na2SO4 and concentrated under
reduced pressure. The residue was purified by flash column
chromatography.
General procedure B (oxidation of secondary alcohols)
To a solution of the appropriate secondary alcohol 3b/3e in
dichloromethane (3 mL) was added manganese(IV) oxide (10
equiv.). The resulting suspension was heated to reflux for 6 h.
After cooling to room temperature, the mixture was filtered
through a pad of celite, and the celite was washed with
dichloromethane (20 mL). The combined organic layers were
concentrated under reduced pressure. The residue was purified
by flash column chromatography.
General procedure C (methylation of secondary alcohols)
To a suspension of sodium hydride (1.5 equiv., 60% in
mineral oil) in dry DMF (1–2 mL) was added a solution of the
appropriate secondary alcohol 3b/3c/3f (1.0 equiv.) in dry DMF
(1–2 mL). The reaction mixture was stirred under nitrogen
atmosphere at room temperature for 30 min, before iodo-
methane (3.0 equiv.) was added. Stirring was continued for 2 h
and then water (15 mL) was added to the mixture. The reaction
mixture was extracted with dichloromethane (3 × 20 mL). The
combined organic layers were washed with brine (2 × 20 mL),
dried with Na2SO4 and concentrated under reduced pressure.
The residue was purified by flash column chromatography.
General procedure D (hydrogenolysis of diaryl methanols)
To a solution of 3b/3d in MeOH (2–10 mL) was added conc.
H2SO4 (0.1–0.5 mL) and 10% Pd/C (0.070 g–0.100 g). The
mixture was stirred under hydrogen atmosphere at room tem-
perature for 6 d. Then the catalyst was filtered off through a pad
of celite and the resulting solution was concentrated under
reduced pressure. Satd. aqueous NaHCO3 solution (20 mL) was
added to the residue, followed by extraction with dichloro-
methane (3 × 20 mL). The combined organic layers were dried
with Na2SO4 and concentrated under reduced pressure. The
residue was purified by flash column chromatography.
General procedure E (Hydrogenolysis of benzyl ethers)
To a solution of 3f/3c in MeOH (10 mL) was added 10% Pd/C
(0.100 g). The mixture was stirred under hydrogen atmosphere
at room temperature for 24 h. Then the catalyst was filtered off
through a pad of celite and the resulting solution was concen-
trated under reduced pressure. The residue was purified by
flash column chromatography.
General procedure F (Photocyclization to give oxoaporphines)
A stirred solution of NaBH4 (0.019 g, 0.500 mmol) and the sec-
ondary alcohol 12a (0.124 g, 0.330 mmol) in MeOH (132 mL)
or 12b (0.130 g, 0.300 mmol) in MeOH (120 mL) was irradiated
in a photo reactor equipped with a medium pressure mercury
vapor lamp (125 W) at room temperature for the indicated
time. The solvent was then evaporated and the residue was dis-
solved in dichloromethane (200 mL). The solution was washed
with water (3 × 50 mL), the organic layer was dried with
Na2SO4 and concentrated under reduced pressure. The residue
was purified by flash column chromatography (dichloro-
methane/methanol = 97 : 3).
(±)-(6,7-Dimethoxyisoquinolin-1-yl)(4-methoxyphenyl)metha-
nol (3a). This compound was prepared following general pro-
cedure A fom 6,7-dimethoxyisoquinoline (1a, 0.189 g,
1.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/toluene;
1.5 mL, 1.50 mmol) and 4-methoxybenzaldehyde (2a, 0.204 g,
1.50 mmol). The crude residue was purified by flash column
chromatography (ethyl acetate/dichloromethane = 2 : 1 + 2%
triethylamine) to give 3a (0.119 g, 37%) as a pale yellow solid.
mp 143–146 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.40 (d,
J = 5.6 Hz, 1H), 7.50 (d, J = 5.6 Hz, 1H), 7.26 (d, J = 8.7 Hz, 2H),
7.07 (s, 1H), 7.06 (s, 1H), 6.82 (d, J = 8.7 Hz, 2H), 6.39 (br s,
1H), 6.15 (s, 1H), 3.98 (s, 3H), 3.80 (s, 3H), 3.75 (s, 3H); 13C
NMR (101 MHz, CDCl3): δ (ppm) = 159.3, 156.9, 152.8, 149.9,
139.0, 136.1, 133.7, 129.1 (2C), 121.0, 119.9, 114.3 (2C), 105.4,
103.4, 72.4, 56.2, 56.0, 55.4; HRMS (ESI): m/z (%) = 326.1390
[M + H]+ (calcd for C19H19NO4: 325.1314); IR (KBr pellet): ν
(cm−1) = 2935, 1829, 1621, 1567, 1504, 1487, 1435, 1418, 1252,
1202, 1160, 1101, 1039.
(±)-(6,7-Dimethoxyisoquinolin-1-yl)(3,4-dimethoxyphenyl)-
methanol (3b, racemic Papaverinol). This compound was
prepared following general procedure A fom 6,7-dimethoxyiso-
quinoline (1a, 0.189 g, 1.00 mmol) with TMPMgCl·LiCl (1.0 M
in THF/toluene; 1.5 mL, 1.50 mmol) and 3,4-dimethoxybenzal-
dehyde (2b, 0.249 g, 1.50 mmol). The crude residue was puri-
fied by flash column chromatography (ethyl acetate/
dichloromethane = 2 : 1 + 2% triethylamine) to give 3b
(0.150 g, 42%) as a yellow solid. mp 135–137 °C; 1H NMR
(500 MHz, CDCl3): δ (ppm) = 8.36 (d, J = 5.6 Hz, 1H), 7.47 (d,
J = 5.6 Hz, 1H), 7.08 (s, 1H), 7.03 (s, 1H), 6.89 (dd, J = 8.2, 2.0
Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 6.76 (d, J = 8.2 Hz, 1H), 6.42
(br s, 1H), 6.11 (s, 1H), 3.95 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H),
3.73 (s, 3H); 13C NMR (101 MHz, CDCl3: δ (ppm) = 156.7,
152.8, 150.0, 149.5, 148.9, 139.0, 136.4, 133.7, 121.1, 120.3,
119.9, 111.1, 110.8, 105.4, 103.4, 72.7, 56.2, 56.0, 56.0, 55.9;
HRMS (ESI): m/z (%) = 356.1491 [M + H]+ (calcd for
C20H21NO5: 355.1420); IR (KBr pellet): ν (cm
−1) = 3342, 2941,
2839, 1620, 1593, 1569, 1513, 1472, 1454, 1403, 1273, 1257,
1237, 1161, 1135, 1065, 1021.
(±)-Benzo[d][1,3]dioxol-5-yl(6,7-dimethoxyisoquinolin-1-yl)-
methanol (3c). This compound was prepared following
general procedure A fom 6,7-dimethoxyisoquinoline (1a,
0.189 g, 1.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/
toluene; 1.5 mL, 1.50 mmol) and piperonal (2c, 0.224 g,
1.50 mmol). The crude residue was purified by flash column
chromatography (ethyl acetate/dichloromethane = 2 : 1 + 2%
triethylamine) to give 3c (0.144 g, 43%) as a yellow solid. mp
74–76 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) = 8.38 (d, J = 5.6
Hz, 1H), 7.49 (d, J = 5.6 Hz, 1H), 7.09 (s, 1H), 7.05 (s, 1H), 6.94
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(dd, J = 7.9, 1.7 Hz, 1H), 6.74 (d, J = 7.9 Hz, 1H), 6.64 (d, J =
1.7 Hz, 1H), 6.41 (br s, 1H), 6.10 (s, 1H), 5.87 (d, J = 1.4 Hz,
1H), 5.84 (d, 3.98 J = 1.4 Hz, 1H), 3.98 (s, 3H), 3.81 (s, 3H); 13C
NMR (101 MHz, CDCl3): δ (ppm) = 156.5, 152.8, 150.0, 148.2,
147.4, 139.0, 137.8, 133.6, 121.6, 121.0, 119.9, 108.2, 107.9,
105.4, 103.3, 101.1, 72.6, 56.1, 56.0; HRMS (ESI): m/z (%) =
340.1179 [M + H]+ (calcd for C19H17NO5: 339.1107); IR (KBr
pellet): ν (cm−1) = 3331, 3011, 2902, 1622, 1571, 1509, 1486,
1273, 1237, 1160, 1038, 976, 859.
(±)-(3-(Benzyloxy)-4-methoxyphenyl)(6,7-dimethoxyisoquino-
lin-1-yl)methanol (3d). This compound was prepared follow-
ing general procedure A fom 6,7-dimethoxyisoquinoline (1a,
0.378 g, 2.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/
toluene; 3.0 mL, 3.00 mmol) and 3-(benzyloxy)-4-methoxybenz-
aldehyde (2d, 0.727 g, 3.00 mmol). The crude residue was puri-
fied by flash column chromatography (ethyl acetate/iso-hexane
= 3 : 1 + 2% triethylamine) to give 3d (0.460 g, 53%) as a pale
yellow solid. mp 137–138 °C; 1H NMR (500 MHz, CDCl3):
δ (ppm) = 8.30 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 5.6 Hz, 1H),
7.22–7.13 (m, 5H), 6.97 (s, 1H), 6.90 (s, 1H), 6.85 (dd, J = 8.2,
2.0 Hz, 1H), 6.74 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 2.0 Hz, 1H),
6.25 (br s, 1H), 6.00 (s, 1H), 4.96 (d, J = 12.3 Hz, 1H), 4.90 (d,
J = 12.3 Hz, 1H), 3.91 (s, 3H), 3.75 (s, 3H), 3.62 (s, 3H); 13C
NMR (126 MHz, CDCl3): δ (ppm) = 156.6, 152.7, 149.9, 149.6,
148.5, 139.0, 137.0, 136.3, 133.6, 128.5 (2C), 127.8, 127.4 (2C),
121.0, 120.9, 119.9, 113.7, 111.8, 105.3, 103.3, 72.6, 71.1, 56.1
(2C), 55.9; HRMS (ESI): m/z (%) = 432.1805 [M + H]+ (calcd for
C26H25NO5: 431.1733); IR (KBr pellet): ν (cm
−1) = 3317, 2951,
2835, 1510, 1403, 1395, 1263, 1236, 1156, 1138, 1068, 1026.
(±)-(4-Methoxyphenyl)(5,6,7-trimethoxyisoquinolin-1-yl)metha-
nol (3e). This compound was prepared following general pro-
cedure A fom 5,6,7-trimethoxyisoquinoline (1b, 0.219 g,
1.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/toluene;
1.5 mL, 1.50 mmol) and 4-methoxybenzaldehyde (2a, 0.204 g,
1.50 mmol). The crude residue was purified by flash column
chromatography (ethyl acetate/iso-hexane = 1 : 1) to give 3e
(0.100 g, 28%) as a pale orange amorphous solid. 1H NMR
(500 MHz, CDCl3): δ (ppm) = 8.42 (d, J = 5.8 Hz, 1H), 7.85 (d,
J = 5.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 2H), 6.91 (s, 1H), 6.83 (d, J =
8.8 Hz, 2H), 6.34 (br s, 1H), 6.14 (s, 1H), 4.02 (s, 3H), 3.96
(s, 3H), 3.79 (s, 3H), 3.75 (s, 3H); 13C NMR (126 MHz, CDCl3): δ
(ppm) = 159.3, 157.0, 153.6, 147.2, 143.9, 138.5, 135.9,
129.1 (2C), 128.9, 122.2, 115.1, 114.3 (2C), 99.7, 72.5, 61.7,
61.3, 56.0, 55.4; HRMS (EI): m/z (%) = 355.1407 (calcd for
C20H21NO5: 355.1420); IR (NaCl film): ν (cm
−1) = 2938, 2835,
1611, 1588, 1510, 1490, 1476, 1396, 1251, 1122, 1061, 1035,
962, 833.
(±)-(7-(Benzyloxy)-6-methoxyisoquinolin-1-yl)(4-(benzyloxy)-
phenyl)methanol (3f ). This compound was prepared follow-
ing general procedure A fom 7-(benzyloxy)-6-methoxyisoquino-
line (1c, 0.265 g, 1.00 mmol) with TMPMgCl·LiCl (1.0 M in
THF/toluene; 1.5 mL, 1.50 mmol) and 4-(benzyloxy)benz-
aldehyde (2e, 0.318 g, 1.50 mmol). The crude residue was puri-
fied by flash column chromatography (ethyl acetate/iso-hexane
= 2 : 1 + 2% triethylamine) to give 3f (0.233 g, 49%) as a pale
yellow solid. mp 107–109 °C; 1H NMR (500 MHz, CD2Cl2): δ
(ppm) = 8.38 (d, J = 5.6 Hz, 1H), 7.53 (d, J = 5.6 Hz, 1H),
7.41–7.38 (m, 6H), 7.38–7.34 (m, 3H), 7.30 (m, 1H), 7.18–7.14
(m, 3H), 7.13 (s, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.14 (d, J = 5.6
Hz, 1H), 6.04 (d, J = 5.6 Hz, 1H), 5.05 (d, J = 11.8 Hz, 1H), 5.01
(s, 2H), 4.95 (d, J = 11.8 Hz, 1H), 3.96 (s, 3H); 13C NMR
(126 MHz, CD2Cl2): δ (ppm) = 158.9, 157.5, 153.7, 149.6, 139.5,
137.6, 136.9, 136.7, 134.2, 129.3 (2C), 129.2 (2C), 129.0 (2C),
128.8, 128.5, 128.2 (2C), 128.0 (2C), 121.2, 120.2, 115.5 (2C),
106.0, 105.5, 72.5, 71.3, 70.5, 56.5; HRMS (EI): m/z (%) =
477.1943 (calcd for C31H27NO4: 477.1940); IR (KBr pellet):
ν (cm−1) = 3403, 3034, 2932, 1606, 1509, 1275, 1237, 1162,
1056, 1009, 743, 695.
(6,7-Dimethoxyisoquinolin-1-yl)(3,4-dimethoxyphenyl)metha-
none (4, Papaveraldine). This compound was prepared follow-
ing general procedure B from 3b (0.129 mg, 0.330 mmol) with
manganese(IV) oxide (0.287 g, 3.30 mmol). The crude residue
was purified by flash column chromatography (ethyl acetate/
dichloromethane = 2 : 1 + 2% triethylamine) to give 4 (0.080 g,
68%) as a white solid. mp 206–208 °C; 1H NMR (500 MHz,
CDCl3): δ (ppm) = 8.45 (d, J = 5.5 Hz, 1H), 7.70 (d, J = 1.9 Hz,
1H), 7.64 (d, J = 5.5 Hz, 1H), 7.54 (s, 1H), 7.42 (dd, J = 8.4, 1.9
Hz, 1H), 7.14 (s, 1H), 6.86 (d, J = 8.4 Hz, 1H), 4.05 (s, 3H), 3.95
(s, 6H), 3.94 (s, 3H); 13C NMR (126 MHz, CDCl3: δ (ppm) =
194.1, 154.0, 153.0, 153.3, 151.2, 149.2, 140.2, 134.1, 130.1,
127.0, 123.0, 121.4, 112.1, 110.1, 105.0, 104.2, 56.3, 56.3, 56.2,
56.2; HRMS (EI): m/z (%) = 353.1292 (calcd for C20H19NO5:
353.1263); IR (KBr pellet): ν (cm−1) = 3424, 3007, 2970, 2933,
1656, 1593, 1582, 1504, 1460, 1433, 1270, 1229, 1140, 1025,
860, 749.
(4-Methoxyphenyl)(5,6,7-trimethoxyisoquinolin-1-yl)metha-
none (5, Thalimicrinone). This compound was prepared fol-
lowing general procedure B from 3e (0.060 g, 0.170 mmol)
with manganese(IV) oxide (0.148 g, 1.70 mmol). The crude
residue was purified by flash column chromatography (ethyl
acetate/iso-hexane = 3 : 2) to give 5 (0.059 g, 98%) as a pale
yellow solid. mp 151–153 °C; 1H NMR (500 MHz, CDCl3): δ
(ppm) = 8.48 (d, J = 5.6 Hz, 1H), 7.98 (d, J = 5.6 Hz, 1H), 7.95
(d, J = 8.9 Hz, 2H), 7.36 (s, 1H), 6.96 (d, J = 8.9 Hz, 2H), 4.08 (s,
3H), 4.03 (s, 3H), 3.93 (s, 3H), 3.88 (s, 3H); 13C NMR (126 MHz,
CDCl3): δ (ppm) = 194.0, 164.2, 154.7, 154.2, 146.9, 144.4,
139.7, 133.4 (2C), 129.9, 129.3, 124.0, 116.7, 113.9 (2C), 100.5,
61.8, 61.4, 56.3, 55.7; HRMS (EI): m/z (%) = 353.1264 (calcd for
C20H19NO5: 353.1263); IR (KBr pellet): ν (cm
−1) = 2944, 1651,
1601, 1479, 1280, 1256, 1163, 1127, 1028, 934, 832.
(±)-1-[(3,4-Dimethoxyphenyl)(methoxy)methyl]-6,7-dimethoxy-
isoquinoline (6a, racemic Setigerine). This compound was pre-
pared following general procedure C using sodium hydride
(60% in mineral oil; 0.014 g, 0.350 mmol) in dry DMF (2 mL),
3b (0.088 g, 0.230 mmol) in dry DMF (2 mL) and iodomethane
(0.040 mL, 0.690 mmol). The crude residue was purified by
flash column chromatography (dichloromethane/methanol =
95 : 5) to give 6a (0.065 g, 77%) as a pale yellow solid. mp
145–147 °C; 1H NMR (500 MHz, CDCl3): δ (ppm) = 8.41 (d, J =
5.6 Hz, 1H), 7.71 (s, 1H), 7.47 (d, J = 5.6 Hz, 1H), 7.05 (d, J = 1.9
Hz, 1H), 7.04 (s, 1H), 6.95 (dd, J = 8.3, 1.9 Hz, 1H), 6.76 (d, J =
8.3 Hz, 1H), 5.85 (s, 1H), 3.98 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H),
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3.79 (s, 3H), 3.46 (s, 3H); 13C NMR (126 MHz, CDCl3: δ (ppm) =
157.2, 152.5, 149.6, 149.0, 148.3, 140.7, 134.2, 133.6, 122.1,
119.8, 118.7, 110.8, 109.7, 105.2, 104.5, 87.2, 57.5, 56.1, 56.0
(3C); HRMS (EI): m/z (%) = 369.1575 (calcd for C21H23NO5:
369.1576); IR (KBr pellet): ν (cm−1) = 3439, 2933, 1512, 1476,
1461, 1428, 1269, 1249, 1225, 1155, 1140, 1108, 1049, 1026,
855.
(±)-1-[Benzo[d][1,3]dioxol-5-yl(methoxy)methyl]-6,7-dimethoxy-
isoquinoline (6b, racemic Setigeridine). This compound was
prepared following general procedure C using sodium hydride
(60% in mineral oil; 0.009 g, 0.230 mmol) in dry DMF (1 mL),
3c (0.050 g, 0.150 mmol) in dry DMF (1 mL) and iodomethane
(0.030 mL, 0.450 mmol). The crude residue was purified by
flash column chromatography (ethyl acetate/iso-hexane = 3 : 1)
to give 6b (0.048 g, 91%) as a brown amorphous solid. 1H
NMR (500 MHz, CDCl3): δ (ppm) = 8.39 (d, J = 5.6 Hz, 1H), 7.69
(s, 1H), 7.46 (d, J = 5.6 Hz, 1H), 7.03 (s, 1H), 6.94 (d, J = 8.1 Hz,
1H), 6.92 (s, 1H), 6.71 (d, J = 8.1 Hz, 1H), 5.87 (d, J = 2.0 Hz,
2H), 5.81 (s, 1H), 3.98 (s, 3H), 3.87 (s, 3H), 3.45 (s, 3H); 13C
NMR (126 MHz, CDCl3): δ (ppm) = 157.1, 152.5, 149.6, 147.7,
146.8, 140.7, 135.0, 134.1, 122.1, 119.8, 119.7, 108.0, 107.2,
105.2, 104.5, 101.0, 87.3, 57.5, 56.0 (2C); HRMS (EI): m/z (%) =
353.1265 (calcd for C20H19NO5: 353.1263); IR (KBr pellet): ν
(cm−1) = 2935, 1829, 1621, 1567, 1504, 1487, 1435, 1418, 1252,
1202, 1160, 1101, 1039.
(±)-7-(Benzyloxy)-1-[(4-(benzyloxy)phenyl)(methoxy)methyl]-
6-methoxyisoquinoline (6c). This compound was prepared
following general procedure C using sodium hydride (60% in
mineral oil; 0.013 g, 0.320 mmol) in dry DMF (2 mL), 3f
(0.100 g, 0.220 mmol) in dry DMF (2 mL) and iodomethane
(0.040 mL, 0.630 mmol). The crude residue was purified by
flash column chromatography (ethyl acetate) to give 6c
(0.093 g, 90%) as a yellow amorphous solid. 1H NMR
(400 MHz, CD2Cl2): δ (ppm) = 8.35 (d, J = 5.6 Hz, 1H), 7.88 (s,
1H), 7.51–7.46 (m, 3H), 7.43–7.29 (m, 10H), 7.10 (s, 1H), 6.88
(d, J = 8.8 Hz, 2H), 5.82 (s, 1H), 5.15 (d, J = 11.9 Hz, 1H), 5.09
(d, J = 11.9 Hz, 1H), 5.02 (s, 2H), 3.97 (s, 3H), 3.38 (s, 3H); 13C
NMR (101 MHz, CD2Cl2): δ (ppm) = 158.5, 157.9, 153.4, 149.2,
141.1, 137.8, 137.1, 134.7, 134.1, 129.2 (2C), 129.0 (2C), 128.7,
128.4, 128.3 (2C), 128.1 (2C), 127.9 (2C), 122.4, 120.1,
115.0 (2C), 106.8, 105.9, 88.0, 71.1, 70.5, 57.6, 56.4; HRMS
(EI): m/z (%) = 491.2097 (calcd for C32H29NO4: 491.2097);
IR (NaCl film): ν (cm−1) = 3032, 2933, 2824, 1610, 1566,
1507, 1477, 1433, 1380, 1250, 1226, 1171, 1158, 1098, 1049,
859, 750.
1-[Hydroxy(4-hydroxyphenyl)methyl]-6-methoxyisoquinolin-
7-ol (7, Annocherin A). This compound was prepared follow-
ing general procedure E from 3f (0.230 g, 0.480 mmol). Flash
column chromatography (ethyl acetate/methanol/triethylamine
= 96 : 2 : 2) afforded 7 (0.128 g, 90%) as a yellow solid. mp
166–168 °C; 1H NMR (400 MHz, MeOD): δ (ppm) = 8.23 (d, J =
5.7 Hz, 1H), 7.57 (d, J = 5.7 Hz, 1H), 7.43 (s, 1H), 7.22 (s, 1H),
7.18 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 6.19 (s, 1H),
3.97 (s, 3H); 13C NMR (101 MHz, MeOD): δ (ppm) = 158.6,
158.1, 153.9, 149.2, 138.6, 135.2, 135.0, 129.5 (2C), 123.1,
121.2, 116.2 (2C), 108.6, 106.4, 74.8, 56.4; HRMS (EI): m/z (%) =
297.0999 (calcd for C17H15NO4: 297.1001); IR (KBr pellet):
ν (cm−1) = 3410, 3180, 2377, 2297, 1611, 1514, 1274, 1229,
1194, 1051, 977, 855, 842.
1-[(4-Hydroxyphenyl)(methoxy)methyl]-6-methoxyisoquino-
lin-7-ol (8, Annocherin B). This compound was prepared fol-
lowing general procedure E from 13 (0.080 g, 0.160 mmol).
Flash column chromatography (dichloromethane/methanol =
9 : 1) afforded 8 (0.033 g, 66%) as a brown solid. mp
178–180 °C; 1H NMR (400 MHz, MeOD): δ (ppm) = 8.19 (d, J =
5.7 Hz, 1H), 7.68 (s, 1H), 7.56 (d, J = 5.7 Hz, 1H), 7.21–7.19 (m,
3H), 6.70 (d, J = 8.7 Hz, 2H), 5.81 (s, 1H), 3.96 (s, 3H), 3.38 (s,
3H); 13C NMR (101 MHz, MeOD): δ (ppm) = 158.1, 157.8,
154.0, 149.2, 139.2, 135.3, 132.5, 129.3 (2C), 123.9, 121.4, 116.0
(2C), 108.9, 106.4, 86.4, 57.4, 56.4; HRMS (EI): m/z (%) =
311.1164 (calcd for C18H17NO4: 311.1158); IR (NaCl film): ν
(cm−1) = 2923, 1611, 1594, 1509, 1479, 1453, 1431, 1345, 1259,
1231, 1195, 1167, 1095, 856, 752.
1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (9,
Papaverine). This compound was prepared following general
procedure D from 3b (0.100 g, 0.280 mmol) in MeOH (10 mL),
conc. H2SO4 (0.5 mL) using 10% Pd/C (0.100 g). The crude
residue was purified by flash column chromatography (methyl-
tert-butylether/ethyl acetate = 1 : 1 + 5% triethylamine) to give 9
(0.057 g, 60%) as a white solid. mp 145–147 °C; 1H NMR
(400 MHz, CDCl3): δ (ppm) = 8.36 (d, J = 5.6 Hz, 1H), 7.41 (d, J
= 5.6 Hz, 1H), 7.33 (s, 1H), 7.03 (s, 1H), 6.83–6.79 (m, 2H), 6.75
(d, J = 8.7 Hz, 1H), 4.52 (s, 2H), 3.98 (s, 3H), 3.89 (s, 3H), 3.80
(s, 3H), 3.75 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) =
157.9, 152.5, 149.9, 149.1, 147.6, 141.2, 133.5, 132.4, 123.0,
120.6, 118.8, 112.0, 111.3, 105.4, 104.3, 56.1, 56.0, 55.9 (2C),
42.4; HRMS (ESI): m/z (%) = 339.1471 [M + H]+ (calcd for
C20H21NO4: 339.1470); IR (KBr pellet): ν (cm
−1) = 2939, 2835,
1617, 1589, 1564, 1506, 1435, 1416, 1260, 1234, 1203, 1158,
1140, 1029, 985.
1-(3-Hydroxy-4-methoxybenzyl)-6,7-dimethoxyisoquinoline (10,
Palaudine). This compound was prepared following general
procedure D from 3d (0.070 g, 0.160 mmol) in MeOH (2 mL),
conc. H2SO4 (0.1 mL) using 10% Pd/C (0.070 g). The crude
residue was purified by flash column chromatography (ethyl
acetate) to give 10 (0.039 g, 75%) as a white solid. mp
179–182 °C; 1H NMR (500 MHz, CD2Cl2): δ (ppm) = 8.24 (d, J =
5.7 Hz, 1H), 7.40 (d, J = 5.7 Hz, 1H), 7.31 (s, 1H), 7.06 (s, 1H),
6.77–6.75 (m, 3H), 6.33 (s, 1H), 4.45 (s, 2H), 3.95 (s, 3H), 3.86
(s, 3H), 3.81 (s, 3H); 13C NMR (101 MHz, CD2Cl2): δ (ppm) =
158.4, 153.2, 150.6, 146.5, 145.9, 141.2, 133.9, 133.6,
123.3, 120.4, 119.1, 115.4, 111.4, 105.8, 104.7, 56.5, 56.4,
56.3, 42.1; HRMS (EI): m/z (%) = 325.1311 (calcd for
C19H19NO4: 325.1314); IR (KBr pellet): ν (cm
−1) = 3439, 2924,
1620, 1586, 1569, 1508, 1480, 1434, 1422, 1277, 1234, 1203,
1161, 1133.
(±)-(2-Bromophenyl)(6,7-dimethoxyisoquinolin-1-yl)methanol
(12a). This compound was prepared following general pro-
cedure A fom 6,7-dimethoxyisoquinoline (1a, 0.189 g,
1.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/toluene;
1.5 mL, 1.50 mmol) and 2-bromobenzaldehyde (11a, 0.278 g,
1.50 mmol). The residue was purified by flash column chrom-
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atography (ethyl acetate/dichloromethane = 1 : 1) to give 12a
(0.258 g, 69%) as a white solid. mp 107–108 °C; 1H NMR
(400 MHz, CD2Cl2): δ (ppm) = 8.40 (d, J = 5.6 Hz, 1H),
7.66–7.62 (m, 1H), 7.56 (d, J = 5.6 Hz, 1H), 7.13–7.09 (m, 3H),
7.04 (s, 1H), 6.90–6.85 (m, 1H), 6.66 (s, 1H), 3.94 (s, 3H), 3.83
(s, 3H); 13C NMR (101 MHz, CD2Cl2): δ (ppm) = 156.8, 153.6,
151.0, 143.2, 139.2, 134.1, 133.4, 130.2, 130.0, 128.7, 124.5,
121.4, 120.5, 105.8, 103.4, 71.6, 56.7, 56.5; HRMS (ESI): m/z (%)
= 374.0389 [M + H]+ (calcd for C18H17BrNO3: 373.0314); IR (KBr
pellet): ν (cm−1) = 3509, 3347, 3057, 2933, 1623, 1572, 1510,
1480, 1437, 1401, 1325, 1276, 1237, 1202, 1161, 1074, 1020, 974.
(±)-(2-Bromo-4,5-dimethoxyphenyl)(6,7-dimethoxyisoquino-
lin-1-yl)methanol (12b). This compound was prepared follow-
ing general procedure A fom 6,7-dimethoxyisoquinoline (1a,
0.189 g, 1.00 mmol) with TMPMgCl·LiCl (1.0 M in THF/
toluene; 1.5 mL, 1.50 mmol) and 6-bromovertraldehyde (11b,
0.368 g, 1.50 mmol). The residue was purified by flash column
chromatography (ethyl acetate/dichloromethane = 1 : 2) to give
12b (0.152 g, 35%) as a white solid. mp 185–186 °C; 1H NMR
(400 MHz, CD2Cl2): δ (ppm) = 8.39 (d, J = 5.6 Hz, 1H), 7.55 (d,
J = 5.6 Hz, 1H), 7.13 (s, 1H), 7.09 (s, 1H), 7.06 (s, 1H), 6.56 (s,
1H), 6.35 (s, 1H), 6.29 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H), 3.80 (s,
3H), 3.49 (s, 3H); 13C NMR (101 MHz, CD2Cl2): δ (ppm) =
157.1, 153.6, 151.0, 150.2, 149.9, 139.2, 135.1, 134.0, 121.4,
120.4, 115.6, 114.3, 112.2, 105.8, 103.6, 71.5, 56.8, 56.6, 56.4,
56.2; HRMS (ESI): m/z (%) = 433.0507 (calcd for C20H20BrNO5:
433.0525); IR (KBr pellet): ν (cm−1) = 3293, 2937, 1619, 1597,
1570, 1508, 1434, 1405, 1271, 1254, 1235, 1200, 1155, 1030,
858.
1,2-Dimethoxy-7H-dibenzo[de,g]quinolin-7-one (13, Lysica-
mine). This compound was prepared following general pro-
cedure F from 12a (0.112 g, 0.300 mmol) to give 13 (0.051 g,
53%) as a yellow solid. mp 181–183 °C; 1H NMR (400 MHz,
CD2Cl2): δ (ppm) = 9.22 (ddd, J = 8.4, 1.1, 0.5, 1H), 8.87 (d, J =
5.2 Hz, 1H), 8.50 (ddd, J = 7.9, 1.7, 0.5 Hz, 1H), 7.85 (d, J = 5.2
Hz, 1H), 7.79 (ddd, J = 8.4, 7.2, 1.7 Hz, 1H), 7.60 (ddd, J = 7.9,
7.2, 1.1 Hz, 1H), 7.29 (s, 1H), 4.09 (s, 3H), 4.03 (s, 3H); 13C
NMR (101 MHz, CD2Cl2): δ (ppm) = 183.0, 157.5, 152.8, 146.0,
145.5, 136.1, 135.1, 134.8, 132.8, 129.2, 129.1, 128.9, 124.1,
122.8, 120.1, 107.2, 61.1, 56.8; HRMS (EI): m/z (%) = 291.0888
(calcd for C18H13NO3: 291.0895); IR (KBr pellet): ν (cm
−1) =
1671, 1607, 1596, 1486, 1460, 1408, 1304, 1260, 1240, 1137,
1042, 1003, 933, 869.
1,2,9,10-Tetramethoxy-7H-dibenzo[de,g]quinolin-7-one (14,
Oxoglaucine). This compound was prepared following general
procedure F from 12b (0.130 g, 0.300 mmol) to give 14
(0.062 g, 59%) as a dark orange solid. mp 212–214 °C; 1H NMR
(400 MHz, CD2Cl2): δ (ppm) = 8.81 (d, J = 5.2 Hz, 1H), 8.77 (s,
1H), 7.90 (s, 1H), 7.77 (d, J = 5.2 Hz, 1H), 7.19 (s, 1H), 4.07 (s,
3H), 4.04 (s, 3H), 4.02 (s, 3H), 4.01 (s, 3H); 13C NMR (101 MHz,
CD2Cl2): δ (ppm) = 181.7, 157.3, 154.4, 151.7, 150.2, 146.1,
145.2, 135.9, 129.7, 127.4, 123.8, 122.2, 120.2, 110.9, 109.9,
106.7, 61.0, 56.7, 56.5, 56.4; HRMS (EI): m/z (%) = 351.1102
(calcd for C20H17NO5: 351.1107); IR (KBr pellet): ν (cm
−1) =
1646, 1593, 1571, 1510, 1462, 1424, 1412, 1360, 1301, 1274,
1240, 1143, 1067, 1001, 883.
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